DXS International plc (AQSE: DXSP): Half-year Financial Report

Core Viewpoint - DXS International plc reported a decline in revenue and a significant loss for the half year ending 31 October 2025, primarily due to reduced grant income and changes in accounting for R&D costs, while maintaining a focus on digital innovation in healthcare [2][8][10]. Financial Highlights - Revenue decreased by 2.6% to £1,684,712 compared to £1,730,829 in H1 2024 [8]. - Loss after tax for the period was £99,041, a change of £100,172 from a profit of £1,131 in H1 2024, largely due to a reduction in grant income by £164,409 [8][11]. - Administration costs decreased by 5% to £1,617,798 [8]. - Available cash at the end of the period was £160,400, an increase from £96,431 in H1 2024 [8][13]. Operational Highlights - The deployment of the new SMART Referral solution, Next-Gen, has received positive feedback from early adopters, which may lead to increased Annual Recurring Revenue (ARR) [8]. - A Secondary Care pilot is running well, aimed at automating referral inputs, potentially creating a new revenue stream [8]. - The company is positioned to provide solutions for tackling Cardiovascular Disease (CVD), with a cholesterol prototype expected to be market-ready soon [8][9]. Post-Period Events - In December 2025, DXS experienced a security incident affecting its office servers, which was contained swiftly, and additional security measures have been implemented [5]. Industry Outlook - The NHS is under pressure to reduce waiting times and address CVD, with digital innovation and preventive care identified as key priorities in its Ten-Year Digital Transformation Plan [6][7]. - The NHS GP IT Futures framework expired on 31 March 2023, leading to a halt in new procurements, with a replacement framework currently in development [6]. Future Prospects - The restructuring of Clinical Commissioning Groups (CCGs) to Integrated Care Boards (ICBs) has created opportunities for DXS, as five ICBs are interested in standardizing on DXS as a single referral solution [9]. - The company anticipates revenue growth beginning around April 2026, driven by NHS commitments to digital transformation [10].